Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new article from a group in the UK suggests that there is no difference in outcomes between patients with localized disease and with Gleason scores of 4 + 3 = 7 or 3 + 4 = 7 when their PSA is ≤ 10 and they are treated with iodine-125-based, permanent seed brachytherapy.
Filed under: Management, Treatment | Tagged: brachytherapy, Gleason score, localized, outcome | Leave a Comment »
The question of when one should initiate hormone therapy in a man who has a rising PSA after radiation therapy has long been a topic of controversy. And a reanalysis of data from RTOG 85-31 has not helped to give us a definitive answer.
Filed under: Management, Treatment, Uncategorized | Tagged: ADT, androgen deprivation therapy, outcome, radiotherapy, timing | Leave a Comment »
A paper to be presented on Sunday at the upcoming annual meeting of the American Association for Cancer Research suggests that “the proliferative index as assessed by Ki-67 immunoreactivity is an independent predictor of aggressive prostate cancer.”
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, differentiation, indolent, Ki-67, marker, prognosis | 2 Comments »
A new epidemiological study from Sweden has suggested that all prostate cancer patients may be at slightly increased risk for thromboembolism (blood clots) compared to men in the general population, but the risk is greatest for men receiving hormone therapies.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: blood clot, risk, thromboembolism | 1 Comment »
A Prostate Cancer Task Force of the International Society of Geriatric Oncology (SIOG) has just issued new recommendations on the management of prostate cancer in “older men” (by which the task force means men of more than 70 years of age).
Filed under: Management, Treatment | Tagged: elderly, geriatric, older, Treatment | Leave a Comment »
One of the proposed uses for high-intensity focused ultrasound (HIFU) has been as a treatment option for men with a rising PSA after first-line treatment with external beam radiation therapy (EBRT).
Filed under: Management, Treatment | Tagged: failure, HIFU, high-intensity focused ultrasound, outcome, radiation, salvage | Leave a Comment »
We have heard that another investigational vaccine therapy has started Phase I clinical trials that will include patients with advanced prostate cancer who “have failed at least 1 course of an accepted hormonal therapy.”
Filed under: Drugs in development, Management, Treatment | Tagged: DPX-0907, trial, vaccine | Leave a Comment »
The desire to find vitamins and foods and similar products (“nutraceuticals” as compared to pharmaceuticals) that have significant and measurable clinical impact on the prevention and/or the actual treatment of prostate cancer has been a constant over the past 20+ years.
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: diet, nutraceuticals, nutrition, vitamins | 1 Comment »
Unsurprisingly, the longer a man older than 65 years goes between PSA tests, the greater is the likelihood that he will be diagnosed with clinically significant prostate cancer that has escaped from the prostate (especially if he has never had a PSA test until he became Medicare eligiible).
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: age, Diagnosis, PSA, race, risk, stage | Leave a Comment »
Based on data from a study published recently in the British Journal of Cancer, media reports have suggested that men in the UK who undergo testing to detect prostate cancer suffer from significant psychological stress.
Filed under: Diagnosis, Risk | Tagged: biopsy, distress, PSA, stress, test | 2 Comments »
There have been a lot of data published on the potential implications of long-term use of statins (e.g., simvastatin/Zocor and atorvastatin/Lipitor) and non-steroidal antianflammmatory drugs (NSAIDs, e.g., aspirin and ibuprofen) in prevention and management of prostate cancer. But what we are really sure of at the moment is limited.
Filed under: Living with Prostate Cancer | Tagged: ACM, all cause mortality, NSAID, statin, survival | 3 Comments »
If you’ve been hoping that research in the field of epigenetics is going to bring us a cure for prostate cancer in the next few years, dream on!
Filed under: Drugs in development | Tagged: drug development, epigenetics | 3 Comments »
In March this year it was announced that the combination of bevacizumab (Avastin) with docetaxel and prednisone had no benficial impact (in a large Phase III trial) on the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. There are, naturally, hopes that the outcome might be different if one adds [...]
Filed under: Drugs in development, Management, Treatment | Tagged: bevacizumab, chemotherapy, docetaxel, hornone-refractory, HRPC, thalidomide | Leave a Comment »
If you’ve recently noticed a 430+ percent increase in your bill for a single shot of leuprolide acetate (to more than $11,000), just click here for the explanation. Oh, sorry, no one can actually give you a coherent explanation (well, not if you got treated at a specific facility in Scottsdale, AZ).
Filed under: Living with Prostate Cancer, Treatment | Tagged: cost, drug, transparency | Comments Off
Search for new and
ongoing trials on the
CTAG PCa web site